Litcius/Paper detail

Molecular Investigation of SARS–CoV-2 Proteins and Their Interactions with Antiviral Drugs

Paolo Calligari, Sara Bobone, G Ricci, Alessio Bocedi

2020Viruses133 citationsDOIOpen Access PDF

Abstract

A new Coronavirus strain, named SARS-CoV-2, suddenly emerged in early December 2019. SARS-CoV-2 resulted in being dramatically infectious, with thousands of people infected. In this scenario, and without effective vaccines available, the importance of an immediate tool to support patients and against viral diffusion becomes evident. In this study, we exploit the molecular docking approach to analyze the affinity between different viral proteins and several inhibitors, originally developed for other viral infections. Our data show that, in some cases, a relevant binding can be detected. These findings support the hypothesis to develop new antiviral agents against COVID-19, on the basis of already established therapies.

Topics & Concepts

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Sars virusCoronavirus2019-20 coronavirus outbreakVirologyComputational biologyDocking (animal)Antiviral drugBiologyMedicineVirusInfectious disease (medical specialty)OutbreakDiseaseNursingPathologySARS-CoV-2 and COVID-19 ResearchInfluenza Virus Research StudiesViral gastroenteritis research and epidemiology
Molecular Investigation of SARS–CoV-2 Proteins and Their Interactions with Antiviral Drugs | Litcius